Background: Postoperative atrial fibrillation (POAF) is a known risk factor for morbidity and mortality after cardiac surgery but has not been investigated in the left ventricular assist device (LVAD) population. We hypothesize that POAF will increase morbidity and resource utilization after LVAD placement.
Perspective
This study clarifies that some known associations of POAF apply to the LVAD population, including increased morbidity and resource utilization. The likely detrimental impact on right heart function should spur further investigation to prevent complications. The impact of these complications represents a great opportunity to translate quality improvement initiatives to the LVAD population.
See Editorial Commentary page 1550.
See Editorial page 1528.
Postoperative atrial fibrillation (POAF) after cardiac surgery is a common complication, occurring after 10% to 40% of cardiac cases. [1] [2] [3] The causes of POAF are multifactorial and include preoperative structural changes and perioperative proarrhythmic adrenergic activation, inflammation, and oxidative stress. 3 Development of POAF is associated with increased risk of morbidity, From the a Division of Thoracic and Cardiovascular Surgery, University of Virginia, Charlottesville, Va; b mortality, and resource utilization, including length of stay (LOS), readmission, and hospital cost. 4 However, the information regarding the impact of POAF after left ventricular assist device (LVAD) implantation is far less well understood. Ventricular arrhythmias garner far more concern than POAF, likely limiting investigation into the clinical and economic impacts of atrial arrhythmias.
Although the complication rate after LVAD surgery is high, at a rate of approximately 30% POAF is one of the most common complications reported. [5] [6] [7] [8] With the cost of LVAD implantation in the hundreds of thousands of dollars, this therapy warrants scrutiny to identify quality and cost-improvement opportunities. [9] [10] [11] The Virginia Cardiac Services Quality Initiative (VCSQI) is a regional consortium of hospitals with the primary goal of improving patient quality, outcomes, and cost. The data available within this cohort represent an ideal opportunity to address quality and cost inefficiencies within a high-cost procedure.
The purpose of this analysis was to identify the potential associations of POAF with complications and resource utilization. We hypothesized that POAF is associated with risk-adjusted morbidity and mortality after LVAD implantation. Furthermore, we believe these differences will be evidenced by increased resource utilization, including postoperative LOS as well as health care-related cost.
PATIENTS AND METHODS Patient Data
The VCSQI is a multistate regional collaborative consisting of 19 hospitals and surgical practices. Eight of these hospitals perform LVAD surgeries. Member hospitals submit administrative, demographic, and clinical data via the Society of Thoracic Surgeons (STS) standardized data entry forms to both VCSQI and the STS national adult cardiac surgery database. Early data versions collected mean pulmonary artery pressure, which were converted to estimated pulmonary artery systolic pressure ([mean pulmonary artery pressure -2]/0.61).
Deidentified records for all continuous-flow LVAD implantations from January 2009 through June of 2017 were extracted from the VCSQI data registry. Continuous-flow LVADs included HeartMate II and III (Thoratec Corp, Pleasanton, Calif) and HVAD (HeartWare, Framingham, Mass). Patients were excluded for missing baseline arrhythmia or POAF data. The primary outcomes of interest were short-term (in-hospital or 30-day) complications and resource utilization. Specifically, the risk-adjusted associations between POAF and morbidity, mortality, LOS, and cost. Clinical variables used standard STS definitions. 12 Operative mortality is defined as either 30-day or in-hospital mortality. Major morbidity includes permanent stroke, prolonged ventilation, reoperation for any reason, renal failure, and deep sternal wound infection.
The primary objective of VCSQI is quality improvement with implementation of solutions across the collaborative. Business associate agreements are in place between VCSQI, members, and the database vendor (ARMUS Corporation, San Mateo, Calif). This analysis represents a secondary analysis of the VCSQI data registry without Health Insurance Portability and Accountability Act patient identifiers and was exempted from institutional review board review at the University of Virginia (IRB #20321).
Cost Data
The VCSQI cost collection, pairing, and estimation methodologies have been previously described. 13, 14 To summarize in brief, STS clinical data are paired with patient-level hospital financial records using Uniform Billing-04 files, which include all final hospital charges. The matching success rate is 99%. The identified charges are sorted based on International Classification of Diseases, Ninth Revision-based revenue codes. Next, the charges are multiplied by a set of cost-to-charge ratios for each hospital that are publicly available and submitted to the Centers for Medicare and Medicaid Services. All costs are presented as 2016 dollars after adjusting for medical inflation using the market basket for the Centers for Medicare and Medicaid Services Inpatient Prospective Payment System. 15 
Statistical Analysis
Categorical variables are presented as counts (%) and continuous variables as median [25th, 75th percentile] due to skewedness except for cost data, which was also presented as mean AE standard deviation. Cost data are presented as both median and mean to more fully understand cost outliers. Patients were stratified by POAF and preoperative atrial fibrillation and compared by univariate analysis. Categorical variables were analyzed by the c 2 test for and continuous variables by Mann-Whitney U test. For univariate analyses, no imputation for missing data was performed.
Multivariable regression modeling assessed the risk-adjusted associations between POAF and morbidity, mortality, and resource-utilization metrics. Predicted associations were adjusted for preoperative and operative risk factors, hospital volume, and operative year with the complete list of covariates listed in Table E1 . All risk factors used in previous LVAD risk models were included, except for aspartate aminotransferase, which is not captured in the data set and pulmonary artery pressures due to the high number missing (Table E1) . 16 For logistic regression models, a stepwise selection methodology was used to limit the number of covariates to 1 per 10 events, whereas for linear regression models all potential covariates were included.
For univariate analyses, missing data points were excluded from the corresponding analysis. For regression modeling, data imputation was performed based on STS methodology used in the creation of the STS risk models. 17 For missing continuous variables, the median cohort value and for categorical variables the lowest risk definition was applied. Some patients were missing multiple laboratory values; thus, if patients were missing 4 or more values, they were excluded from the regression models (n ¼ 203). All statistical analyses were carried out using SAS Version 9.4 (SAS Institutive, Cary, NC) with significance determined by a P value less than .05.
RESULTS

Patient and Operative Characteristics
A total of 1064 patients underwent implantation of a continuous-flow LVAD, of whom 375 (35%) had a history of atrial fibrillation. Of the 689 patients without a history of atrial fibrillation, 568 (17.6%) developed POAF. The Table 2 , with neither cardiopulmonary bypass time nor application of a complete crossclamp different by development of POAF. The rate of HeartWare HVAD implantation was greater in the POAF cohort (27% vs 18%), with the converse true for HeartMate II (82% vs 72%, P ¼ .02). Patients who developed POAF also had a greater rate of concomitant tricuspid surgery.
Postoperative Outcomes and Resource Utilization
By univariate analysis, POAF was associated with greater rates of multiple morbidities, as shown in Table 3 . The rate of major morbidity was 16% greater in the POAF cohort (P ¼ .001), with many of the component complications similarly elevated. The rate of unplanned right ventricular assist device (RVAD) was more than double in the POAF group (4% vs 10%, P ¼ .02). In addition to complications, resource utilization was greater in patients who developed POAF. POAF was associated with a more than doubling of discharges to a facility (P<.0001), although readmission rates were similar. Both intensive care unit (ICU) and postoperative LOS were longer in patients with POAF (both P <.001). The unadjusted median total hospital cost was significantly greater for patients who developed POAF ($300 
Risk-Adjusted Outcomes and Resource Utilization
POAF continued to be associated with increased morbidity and resource utilization after risk-adjustment, Tables E2-E12 . The most widely associated variable was POAF, which was significant in 6 of 11 models. Also widely associated with outcomes were last hematocrit level (4 models) and last total albumin level (6 models). The least useful variables for risk prediction were preoperative inotropes (0 models), last platelet count (1 model 
DISCUSSION
This study analyzes the impact of atrial fibrillation on risk-adjusted morbidity, mortality, and resource utilization, including hospital costs in a large regional cohort of patients with continuous-flow LVAD. Of the 689 patients who underwent LVAD placement and did not have a history of atrial fibrillation, 121 (17.6%) developed POAF. The development of POAF was associated with a risk-adjusted increase in major morbidity (OR 2.5) but not mortality. There was a strong risk-adjusted association between POAF and unplanned RVAD (OR 2.9) as well as a trend toward renal failure (OR 2.0). In addition, POAF was broadly associated with increased resource utilization, including discharges to a facility and LOS. This includes a 5-day increase in postoperative LOS, most of which was spent in the ICU (88 additional hours). Although there are contemporary estimates of the impact of POAF in coronary and valve surgery, to our knowledge this represents the first estimates in the LVAD population. The incidence of POAF after cardiac surgery has been reported to range from 10% to 40%. 4 However, there are far fewer estimates for rates of atrial fibrillation after LVAD surgery. In this analysis, the overall rate of POAF was 17.6%. This rate is both consistent with the coronary and valve surgery rates, as well as previously reported rates after LVAD implantation of 13% to 32%. 5, 7, 8, 18 These numbers are somewhat surprising, given that LVAD implantation decreases left atrial pressure and size and has been shown to reduce atrial arrhythmias in the long term, where more than 40% of patients with previous atrial fibrillation will never have a recurrence in longterm follow-up. 18 Although POAF is thought to be brought on by unique perioperative stressors, insight can be gained by noting paroxysmal and permanent atrial fibrillation have drastically different trajectories after LVAD placement, with the former improving and the latter causing increased risk of long-term mortality. 18, 19 Right heart failure is the likely culprit, as permanent atrial fibrillation will continue to compromise right ventricular filling. 20, 21 This is supported by the fact that these patients have greater rates of hospitalization for heart failure and right heart failure as a cause of death. 19, 22 Although POAF increases the risk of mortality after coronary and valve surgery, this was neither demonstrated in this study, nor was POAF found to increase the risk of shortor long-term mortality after LVAD placement in other studies. 1, 4, 5, 7 Despite a lack of impact on operative mortality, POAF was highly associated with STS-defined major morbidities. This correlates with the coronary and valve literature but has not been shown previously in the LVAD population. 4, 23 This association appears to be driven by right heart dysfunction and results in a significantly greater risk for unplanned RVAD and a trend of increased renal failure. Although the risk factors for heart failure and atrial fibrillation are similar and the causality cannot be determined from this study, evidence would suggest that POAF is both a cause and symptom of right heart failure. Similar arguments for why permanent atrial fibrillation disrupt right ventricular function apply to POAF. In addition, many patients after LVAD placement have high right-sided pressures increasing the risk of both heart failure and atrial fibrillation, which is borne out by the greater median pulmonary artery pressures in the POAF cohort. 21 Finally, it is also been shown that treatment of atrial fibrillation with ablation improves right heart symptoms. 24 Importantly, the component complication of permanent stroke was not associated with the development of POAF. 5 This is contrary to other cardiac surgery populations, where POAF increases the risk of stroke, although these patients are not routinely anticoagulated. 4 In addition, the current literature is mixed with regard to atrial fibrillation and risk of thromboembolic events, with controversy ignited when preoperative atrial fibrillation was found to increase the risk of late events. 25 Recent literature is more consistent with our findings that neither preoperative atrial fibrillation or POAF are associated with increased rate of stroke. 5, 19, 26, 27 Resource utilization was found to be increased in patients with LVADs who develop POAF, both in the unadjusted and risk-adjusted analyses. In other cardiac surgery procedures, POAF is associated with increases of 48 hours in the ICU and 3 additional postoperative days. 4, 23 These represent approximately 100% and 50% increases based on respective median LOS for patients without POAF. Similarly, in this study POAF was associated with a riskadjusted increase in ICU LOS of 88 hours, a 52% increase over the median ICU LOS of 168 hours for patients without POAF. The increase of 5 days postoperatively in the POAF group represents a 26% increase over the median of 19 days in the non-POAF cohort. These results and a lack of association with mortality indicate that POAF has similar effects in LVAD and other cardiac procedures, although the relative effect size is smaller in this population. However, due to the high complication rates and resource utilization, the impact is still decidedly notable and clinically relevant with larger absolute increases in LOS. This is the first time POAF has been identified as predictive of increased LOS after LVAD implantation, as other analyses have not included this as a risk factor in their models. 28 This study has limitations, many of which are inherent to any retrospective analysis of a multi-institutional database, such as a risk of selection bias. This design prevents causal determination and in particular the timing and relationship of atrial fibrillation to other complications cannot determined. Furthermore, we are constrained by the dataset available that includes unique information such as cost but also lacks detailed information present in other databases or common in atrial fibrillation-specific trials as well as INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support). Some patients were missing multiple laboratory values, preventing the entire cohort from being included in the risk-adjustment analysis. The risk-adjustment performed requires regression models be built for each outcome of interest, increasing the risk of a type I error, the false-positive rate. However, compared with other options, this has the advantage of not requiring matching on a postoperative event and using risk models that have been previously validated in large cohorts. Finally, findings were limited by the short-term nature of all STS related databases.
CONCLUSIONS
POAF is an underappreciated complication after LVAD implantation. The development of POAF was associated with a risk-adjusted increase in not only major morbidity but also resource utilization. This is likely driven by right ventricular failure both causing and worsened by the atrial fibrillation. This correlated with increased renal failure and unplanned RVAD placement. The result is both ICU and postoperative LOS significantly increase with POAF. Contrary to some findings and the coronary/valve literature, POAF was not associated with either mortality or permanent stroke. The significant implications of POAF in the setting of a high-resource utilization surgery make it a prime target for quality improvement measures. Lessons learned in prophylaxis and treatment with other cardiac surgeries may translate to the LVAD population. Further study is warranted to help limit the burden identified by this analysis.
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